Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO

Dec 28 2016

• By Sue Sutter

Related Content

Exondys 51 Clinical Development Timeline

Dec 28 2016

Exondys 51 Reviewers

Dec 28 2016

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'

Dec 28 2016

Hoping To Smooth Relations With FDA, Sarepta Moves On From CEO Garabedian

Apr 01 2015

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Related Companies

Sarepta Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

PTC Therapeutics, Inc.

Additional Topics

Regulation Review Pathway Drug Review BioPharmaceutical Neurology

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window